The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America have recently issued updated evidence-based guidelines on the epidemiology, diagnosis, treatment, and infection control and environmental management of Clostridium difficile infection (CDI) in adults. The guidelines were issued to reflect the marked changes in the epidemiology and manifestations of CDI during the past decade (and since a Society for Healthcare Epidemiology of America guideline on CDI was published in 1995). This review highlights key recommendations from the new guidelines.
From the Department of Microbiology, Leeds Teaching Hospitals & University of Leeds, Old Medical School, Leeds General Infirmary, Leeds, UK.
Correspondence to: Mark H. Wilcox, MD, Department of Microbiology, Leeds Teaching Hospitals & University of Leeds, Old Medical School, Leeds General Infirmary, Leeds LS1 3EX, UK. E-mail: firstname.lastname@example.org.
The author has no funding or conflicts of interest to disclose.
Prof. Wilcox is an advisory board member for Actelion, Astellas, Cerexa, J&J, MSD, Nabriva, Novacta, Optimer, Phico Therapeutics, The Medicines Company, and Viropharma. He is currently a consultant to Cerexa, Pfizer, Photopharmica, Summit, and Wyeth and has research collaborations with Actelion, Novacta, Summit, and The Medicines Company.